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Abstract
Using exome sequencing and a variant prioritisation strategy that focuses on loss-of-function
variants, we identified biallelic, loss-of-function CEP57 mutations as a cause of constitutional
mosaic aneuploidies. CEP57 is a centrosomal protein and is involved in nucleating and stabilizing
microtubules. Our data indicate that these and/or additional functions of CEP57 are crucial in
maintaining correct chromosomal number during cell division.
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Cell division is a highly complex process that involves chromosomal duplication and
separation into two daughter cells. Errors in this process result in gains or losses of
chromosomes, which is known as aneuploidy. Aneuploidy is a significant cause of human
disease, causally implicated in miscarriage, developmental disorders and cancer 1-2. Multiple
biological processes, including mitotic checkpoints, chromatid attachment mechanisms and
centrosome, kinetochore and microtubule functions are required to prevent aneuploidy 1-2.
Mosaic variegated aneuploidy syndrome (MVA; MIM 257300) is a rare, autosomal
recessive disorder characterised by mosaic aneuploidies, diverse phenotypic abnormalities
and predisposition to cancer 3-4. Study of this rare condition can inform on the basic
processes controlling aneuploidy in humans. For example, we previously demonstrated that
biallelic BUB1B mutations cause MVA, linking mitotic spindle defects to human disease
and providing some of the strongest evidence that aneuploidy can be a cause, as well as a
consequence, of cancer 4.
BUB1B mutations underlie only a proportion of MVA and we adopted an exome sequencing
strategy to identify additional causes. We undertook exome sequencing in two siblings with
MVA, (ID 633_1 and 633_2), in whom we previously excluded BUB1B mutations 3. We
used exome capture followed by paired-end sequencing on an Illumina GAIIx Solexa
sequencer (Supplementary Methods). 90% of target bases in the resulting sequence had ≥
10x coverage. We used NextGENe software to detect sequence variants and applied a series
of filters to identify the variants that were most likely to be causative of MVA.
(Supplementary Methods, Supplementary Table 1). We removed variants with read
coverage <10 and/or with a wildtype / mutant ratio of <30% as these are more likely to be
false. We also removed variants in known pseudogenes. As MVA is a very rare condition
we removed all variants present in 50 exomes we have performed in individuals with other
conditions and all variants recorded in dbSNP and/or 1000 Genomes. We also removed all
synonymous and intronic variants outside splice junctions, as these are unlikely to be
causative. After these filters there were 439 variants in sibling 1 and 439 in sibling 2. We
used this final dataset in the analyses outlined below.
We first applied a loss-of-function (LOF) script that identifies nonsense mutations, coding
insertions or deletions that result in translational frameshifts, and insertions, deletions or
base substitutions at consensus splice residues (Supplementary Methods). We removed LOF
variants in genes in which we had identified >1 LOF variant in the 50 in-house exomes on
the assumption that LOF variants detected in such genes are too common to cause MVA
and/or are more likely to be artefactual. After this, there remained 20 LOF variants in sibling
1 and 24 in sibling 2 (Supplementary Table 2). We focussed our analyses on LOF variants in
the first instance because of the strong prior evidence of association of this class of mutation
with human disease.
There was no history of consanguinity in family 633 and therefore our expectation was for
the siblings to be compound heterozygotes for two different pathogenic mutations in the
same gene. We identified no genes with two different LOF mutations and 12 genes with one
LOF mutation shared by the two siblings (Supplementary Table 2). We next applied a
conventional recessive script to identify all genes with two variants present in both siblings.
There were no genes with one LOF mutation together with a second variant. There were
four genes with two non-LOF variants that were both present in each sibling, but none were
likely to be causative (Supplementary Table 3).
Of the twelve genes with one shared LOF mutation in the siblings, CEP57 was notable
because it localises to the centrosome 5-6. Using Sanger sequencing we confirmed the
CEP57 520_521delGA deletion detected through the exome sequencing and identified a
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second LOF mutation, an 11bp insertion, c.915_925dup11, which was also present in both
siblings (Supplementary Methods, Supplementary Figures 1 and 2, Supplementary Table 4).
This insertion is a duplication of the preceding 11 bases (Supplementary Figure 2). Analysis
of parental DNA demonstrated that the deletion was present in the father and the duplication
in the mother, consistent with autosomal recessive inheritance. On review of the exome data
the 11bp insertion was clearly present in 30-40% of reads in each sibling. However, it had
not been called in many reads, particularly those in which the insertion was towards the end
of the read, presumably because the reduced flanking sequence impaired alignment. As a
result, the mutant / wildtype read ratio was below the NextGENe calling threshold in both
siblings, and the insertion was disregarded (Supplementary Table 1, Supplementary Figure
3).
We used Sanger sequencing to analyse CEP57 in 18 cases from 13 additional BUB1B-
negative families with MVA and identified two further individuals with biallelic CEP57
mutations, confirming the causative role of CEP57 in aneuploidy predisposition (Table 1,
Supplementary Figure 2). Child 638 was homozygous for a nonsense mutation, c.241C>T;
p.R81X, and each of his parents, who are first cousins, are heterozygous for the mutation.
Child 657 is homozygous for c.915_925dup11 and using dosage analysis we confirmed that
the duplication was present on both of his alleles (Supplementary Methods, Supplementary
Figure 4, Supplementary Table 5). This child was fostered and no parental samples or
information regarding a possible relationship between his parents is obtainable 7.
There were some shared clinical features in the CEP57 cases (Table 1 and Supplementary
Methods). All the affected individuals had random gains and losses of chromosomes in
~25-50% of examined cells (Figure 1a). They all had growth retardation at the milder end of
the spectrum but with relative sparing of the head. There was no gross dysmorphology and
development was normal or mildly delayed. Of note, two of the cases had hypothyroidism
and two had rhizomelic shortening of the upper limbs which may be specific, associated
features of CEP57 mutations.
CEP57 encodes a 500 amino acid protein 5. Secondary structure prediction suggests it is
composed of two α-helical coiled-coil domains connected by a flexible linker region (Figure
1b). The N-terminal coiled-coil domain is within a region required for localisation of CEP57
to the centrosome and for multimerization of the protein. The C-terminal half of CEP57,
including the second coiled-coil domain, is required for nucleating, bundling and anchoring
microtubules to the centrosomes within basket-like structures 6. In addition CEP57 is
involved in intracellular bidirectional trafficking of factors, such as FGF2, along
microtubules 8.
The centrosomal localisation and microtubular stabilisation functions may explicate why
CEP57 loss results in aneuploidy. However, it should be noted that CEP57 is a relatively
under studied protein and it may be that other, currently uncharacterised, functions result in
the phenotype we observed in individuals with biallelic inactivating CEP57 mutations.
BUB1B, which encodes BUBR1, primarily prevents aneuploidy through a mechanism in
which CEP57 is currently not known to have a role, functioning in the mitotic spindle
checkpoint and to maintain stable interactions between microtubules and the
kinetochore 9-10. The phenotypes associated with BUB1B and CEP57 mutations are broadly
similar although BUB1B mutations are strongly associated with cancer 3-4. Thus far no
cancers have been reported in CEP57 mutation-positive individuals, but the number and
ages of individuals is low. The role of CEP57 as a somatic target in cancer has not been well
interrogated 11. Given that aneuploidy is present in >90% of solid tumors, our results
suggest that further analyses would be of interest.
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Exome analysis is proving successful in the identification of many Mendelian disease
genes 12. However, the downstream processes of variant calling, filtering, interpretation and
prioritisation for follow-up, remain challenging. In particular, many commonly used
algorithms find insertion and deletion variants difficult to call with high sensitivity and
specificity 13. As a result, thus far, the majority of new disease genes identified through
exome analyses were discovered through the detection of base-substitution mutations 12.
Although some LOF mutations, such as nonsense and some splicing mutations result from
base substitutions, the majority are due to insertions or deletions. Thus, currently, many
exome analyses are not optimally configured for disease gene identification. We have
optimised a calling strategy with good sensitivity for small insertions and deletions and this
allowed us to detect one of the CEP57 mutations (a two base-pair deletion). However, large
insertions, such as the second CEP57 mutation, remain challenging to call and particular
focus on improving insertion / deletion detection is required for the full potential of exomic
analyses to be realised.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
CEP57 structure, mutations and resulting aneuploidy (a) Aneuploid metaphase karyotypes
from family 633, showing gains and losses of whole chromosomes. (b) Schematic
representation of the genomic structure of CEP57 with the positions of mutations indicated
with arrows. Below is the protein structure showing the coiled-coil domains, the
centrosomal localisation region and microtubular stabilisation region.
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Table 1
CEP57 mutations and associated clinical features
Case ID 663_1 663_2 638 657
Mutations c.520_521delGA
c.915_925dup11
c.520_521delGA
c.915_925dup11
c.241C>T; p.R81X
c.241C>T; p.R81X
c.915_925dup11
c.915_925dup11
Age 8.5yrs 4.5yrs died 3wks died 15yrs
Clinical Features Mosaic aneuploidies yes yes yes yes
Growth retardation yes yes yes yes
Microcephaly no yes no yes
IUGR no yes yes no
Mental retardation no no n/a mild
Congenital heart
disease no no yes mild
Hypothyroidism yes no n/a yes
Rhizomelic shortening no no yes yes
Other features none none duodenal atresiahypotonia
hearing impairment
sleep apnea
Reference 3 3 4 7
a
More detailed clinical information is given in the Supplementary Material
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